Colorectal Cancer

Edward Chu, MD, MMS, discusses the role of pembrolizumab in patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer.

Although most younger patients received diagnoses of cancer of the rectum or distal colon, incidence rates are increasing across all colorectal anatomic subsites.

As first-line therapy for patients with microsatellite instability-high and/or mismatch-repair deficient metastatic colorectal cancer, pembrolizumab improves quality of life compared with standard chemotherapy.

Timothy Cragin Wang, MD, discusses the advent of immunotherapy and how it has revolutionized multiple areas of cancer treatment; however, the transformative potential of the modality has been mild in the field of colorectal cancer.

Caroline Farrington, PhD, ​discusses the importance of patient advocacy in colorectal cancer.

Noam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.

Axel Grothey, MD, discusses factors to consider when selecting between regorafenib and trifluridine/tipiracil in metastatic colorectal cancer.

Heinz-Josef Lenz, MD, FACP, discusses optimal sequencing strategies for the treatment of patients with colorectal cancer.

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Thorvardur (Thor) Halfdanarson, MD, discusses investigational agents that are being evaluated in patients with colorectal cancer who do not harbor genomic alterations.

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Axel Grothey, MD, explains the impact of tumor sidedness on treatment decisions and highlights novel later-line approaches that are under examination in colorectal cancer.

Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.

The approval of encorafenib in combination with cetuximab advances the metastatic colorectal cancer paradigm, introducing a biomarker-specific regimen for patients with pretreated BRAF V600E–mutant disease.

Axel Grothey, MD, discusses biomarkers that can help to guide the treatment of metastatic colorectal cancer.

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

Edward Chu, MD, MMS, discusses the impact of the phase 3 MK-3475-177/KEYNOTE-177 trial in ​metastatic colorectal cancer.

Thorvardur (Thor) Halfdanarson, MD, discusses novel approaches under investigation in the later-line treatment of patients with CRC.

Newer, cheaper and more personalized tests means more people tested and more lives saved.

Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.

Shai Friedland, MD, discusses the novel multimodal FirstSight test, which showed promise in identifying colorectal cancer, as well as precancerous polyps and advanced adenomas.

Thierry Andre, MD, discusses the results of the KEYNOTE-177 trial in metastatic colorectal cancer.

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the addition of celecoxib to standard chemotherapy, stating that it did not significantly improve disease-free survival or overall survival in patients with colon cancer.

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment approaches that are generating excitement in colorectal cancer.